AIxMed and PathNet Partner to Advance AI-Powered Urine Cytology in Digital Pathology
California-based AIxMed has formed a strategic partnership with diagnostic laboratory PathNet to enhance digital pathology workflows through the integration of artificial intelligence. The collaboration brings AIxMed’s AIxURO technology—an AI-powered solution for urine cytology—into PathNet’s digital platform, expanding its capabilities in diagnostic precision and efficiency.
AIxURO is designed to assist in the non-invasive assessment of bladder cancer by analyzing urine cytology specimens using The Paris System for Reporting Urinary Cytology. The software automatically identifies atypical or suspicious cells, helping pathologists make more accurate and consistent evaluations. By supporting early detection and reducing the need for invasive procedures like cystoscopies, the technology aims to improve both clinical decision-making and patient experience.
“We are pleased to partner with AIxMed and add their expertise in urine cytology to our growing portfolio of digital solutions,” said Jason Camilletti, CEO of PathNet. “This partnership reflects our ongoing commitment to patient care by integrating valuable capabilities that meet the specific needs of our diverse customer base and enhance diagnostic pathways.”
AIxMed CEO Samuel Chen emphasized the value of embedding AIxURO into real-world lab environments. “We recognize PathNet as a laboratory leader in urine cytology diagnostics,” Chen said. “We are excited to provide an integrated and tested solution within their workflow, allowing PathNet to triage their cases, improve their quality control, and make their work more efficient.”
Founded in 2018, AIxMed focuses on advancing cancer diagnostics and monitoring through computational cytology. Its flagship product, AIxURO, is currently available for research use and aims to support improved clinical insight through digital sample analysis. PathNet, a U.S.-based digital pathology laboratory, continues to expand its technology-driven services to deliver faster processing times and more personalized diagnostic results. The partnership underscores a growing trend toward AI integration in laboratory medicine, reflecting a shift toward smarter, data-driven diagnostic care.
